Drugs / BMS-986369
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06535399 | Aug 2024 → Nov 2025 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05567510 | Oct → Dec 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05350800 | Sep 2022 → May 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06035497 | Nov 2023 → Jan 2027 expected | T-cell non-Hodgkin lymphoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986369 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06535399 ↗ |
| Route | Oral | “single ascending oral doses (SAD)” NCT05350800 ↗ |